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Abstract
The lung just like all other organs is affected by age. The lungmatures by the age of 20 and age-related
changes start aroundmiddle age, at 40–50 years. Exhaled nitric oxide (FENO)has been shown to be
age, height and gender dependent.We hypothesize that the nitric oxide (NO) parameters alveolarNO
(CANO), airwayﬂux (JawNO), airway diffusing capacity (DawNO) and airwaywall content (CawNO)
will also demonstrate this dependence. Data fromhealthy subjects were gathered by the current
authors from their earlier publications inwhich healthy individuals were included as control subjects.
Healthy subjects (n= 433) ranged in age from7 to 78 years. Age-stratiﬁed reference values of theNO
parameters were signiﬁcantly different. Gender differences were only observed in the 20–49 age group.
The results from themultiple regressionmodels in subjects older than 20 years revealed that age,
height and gender interaction together explained 6%of variation in FENOat 50ml s
−1 (FENO50), 4%
in JawNO, 16% inCawNO, 8% inDawNOand 12% inCANO. In conclusion, in this studywe have
generated reference values forNOparameters from an extendedNOanalysis of healthy subjects. This
is important in order to be able to use these parameters in clinical practice.
Introduction
The use of non-invasive methods to diagnose respira-
tory diseases and monitor treatment is advantageous
for both patients and healthcare professionals. Exhaled
nitric oxide (FENO) has been used extensively since its
discovery in human breath [1], especially in asthma
where clinical practice guidelines have already been
published [2]. The pulmonary nitric oxide dynamics
models have the advantage of being a more precise
assessment of nitric oxide (NO) dynamics, but their
application has been limited [3]. The technical develop-
ment has rapidly evolved and today we have NO
analysers adopted for clinical use, both in specialized
respiratorymedicine andprimary care [4, 5].
FENO from one single exhalation will give a mea-
sured value of NO production from the entire respira-
tory system. A more detailed insight can be gained
through the use of the mathematical two-compartment
model (2CM) of pulmonary NO dynamics, which dif-
ferentiates the NO exchange of the peripheral and cen-
tral parts of the lung and explains the ﬂow dependence
of FENO [6, 7]. In brief, the 2CM consists of an alveolar
compartment comprising the peripheral gas exchanging
parts of the lung (respiratory bronchioles and alveoli)
and an airway compartment comprising the conductive
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airways larger than respiratory bronchioles. Gas in the
alveolar compartment holds a certain concentration of
NO (CANO). During exhalation, alveolar gas travels
through the bronchial compartment and more NO dif-
fuses from the bronchial wall into the luminal gas (air-
way NO ﬂux, JawNO) [8]. CANO and JawNO can be
estimated based on a linear model if FENO is measured
at three ﬂow rates at of least 100ml s−1 [9]. If a ﬂow rate
less than 30ml s−1 is used together with a median and a
high ﬂow rate, i.e. 100 and 300ml s−1, then a non-linear
model can be applied which also estimates the airway
wall concentration of NO (CawNO) and the diffusing
capacity of NO from the airway wall to the gas stream
(DawNO) [8, 10]. Investigations have used the 2CMwith
interesting results, especially for CANOwhere increased
values have been found in severe asthma [11], alveolitis
[12], and chronic obstructive pulmonary disease [10, 13]
and early scleroderma [14]. CANO has been speciﬁcally
used to identify scleroderma patients at high risk for
lung function deterioration and advancing disease, with
5.3 ppbbeing suggested as the cut off value [15].
Reference values are necessary for any new
method to be accepted in clinical practice, and refer-
ence values for FENO at the recommended ﬂow of
50 ml s−1 (FENO50) have been published [16, 17].
Height, age and gender have been shown to inﬂuence
FENO50. Reference values for NO parameters from
extended NO analysis are limited to two publica-
tions, one with 89 adults [18] and one with 66
children [19]. The lung matures by the age of 20 in
regard to closing volume [20] and in older age the
diffusing capacity declines in a linear fashion with
increasing age [21], and these changes in pulmonary
physiology might also affect NO parameters. The
aim of this study was to establish reference values for
NO parameters in healthy subjects ranging from
young to old age.
Methods
Subjects
Data fromhealthy non-smoking subjects were gathered
by the current authors from their earlier publications in
which healthy individuals were included as control
subjects [10, 14, 18, 19, 22–30]. In the majority of these
studies measurements of lung function and symptom
questionnaires veriﬁed the health status. Gender, age
and height were noted. The exhaled ﬂow together with
corresponding exhaledNO levelswere collected.
NOanalysis
FENO50 and FENO values from exhalation with ﬂows of
5–500ml s−1 for the extended NO analysis were gath-
ered. All data were recalculated either with the linear
model (Tsoukias & George, TG) [9] using three ﬂow
rates of at least 100ml s−1 or with the non-linear model
(Högman-MeriläinenAlgorithm,HMA) [10, 22]using a
low ﬂow rate of 5, 10 or 20, a median rate of 100 and a
high ﬂow rate of 300, 400 or 500ml s−1. Data were fed
into an algorithm in a standard Microsoft® Excel
environment, available as supplementary information,
for the estimation of the NO parameters (stacks.iop.
org/JBR/11/047103/mmedia). When generating NO
parameters from the linear model [9], Pearson’s r-value
was noted. With the use of NO parameters from the
non-linear model [10, 22] a plot of ﬂow with corresp-
onding NO values can be generated; at a ﬂow of
50ml s−1, a NO value was noted and compared to the
measured FENO50 for a quality control of the estimation
of the NOparameters. With the non-linear model there
is also a built-in quality test of the curve [10]. This is in
line with the ﬁrst guidelines for the extended NO
analysis [31].
Statistical analysis
Due to aging of the lung, the subjects were divided into
three age groups, <20 years, 20–49 years and 50
years. Descriptive data of the subjects are presented as
frequency or as medians and quartiles where appro-
priate. The distributions of the NO parameters,
stratiﬁed by age groups, are presented as an arithme-
tical mean or geometrical mean (for skewed distribu-
ted data) and as 2.5th, 5th, 25th, 50th, 75th, 95th,
97.5th percentiles. A Kruskal-Wallis test and one-way
ANOVA were used to test for differences in the
distribution of NO parameters between the age
groups. In the case of signiﬁcant difference between
age groups, post-hoc tests were performed using a
pairwise Mann-Whitney U-test. Pearson Correlation
was used to test correlations to CANO. Spearman’s
rank order correlation was used for the other NO
parameters.
Gender-stratiﬁed simple regression models were
ﬁtted with the logarithms of FENO50, CawNO,DawNO,
and JawNO, respectively, as the dependent variable,
and with age as an independent variable. Logarith-
mically scaled regression lines were retransformed
back into natural scale and all regression lines were
then plotted along with their corresponding 95%
reference intervals.
Multiple regression modelling was performed on
data where subjects younger than 20 years were exclu-
ded, as children differ from adults in regards to the
relationship between age and height, which made if
difﬁcult to ﬁt robust statistical models. The models
were speciﬁed with the CANO in natural scale, the
logarithms of FENO50, CawNO, DawNO, and JawNO,
respectively, as the dependent variable, and with age,
height and gender, including interaction terms
between gender*height and gender*age, as indepen-
dent variables. For all themodels, ANOVA chunk tests
were performed, jointly testing if the two interaction
terms contributed signiﬁcantly to the models as com-
pared to omitting them from the model. As this was
not the case for any of the NO parameters, the models
were reﬁtted without the interaction terms. To
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account for a potential cluster effect in the data, we
also controlled for study centre and estimation
method (TG versusHMA). To help the interpretability
of regression coefﬁcients, the variables age and height
were centred and age was scaled to a unit of 10 years
and 10 cm respectively [32]. For the factor gender, B
represents the expected ratio in geometrical means
between a male and a female, keeping all other vari-
ables ﬁxed. For the logarithmically transformed para-
meters, regression coefﬁcients have been
retransformed to natural scale using the exponential
function. The bootstrap procedure produces opti-
mism-corrected estimates of R2, with a correction fac-
tor based on the average difference, in over 5000
bootstrap samples, between the R2 of the model ﬁt to
the bootstrap data and the R2 of the bootstrap model
applied to the original data.
Model assumptions of normality and homo-
scedasticity of residuals were assessed from graphs. A
p-value <0.05 was considered statistically signiﬁcant.
Excel (MicrosoftR Ofﬁce 2011) was used for calcula-
tions of the NO parameters. Statistical analyses were
performed using SPSS, v. 22 (SPSS Inc., Chicago, MI,
USA), andR [33] using the rms package [34].
Results
Healthy subjects (n = 433) aged between 7–78 years
were analysed. There were more men (n = 268) than
women (n= 165) (table 1). There was no difference in
FENO50 between the study centres (p= 0.37).
The NO parameters were estimated using the lin-
ear model TG (n = 87) with an r-value from 0.90 to
1.0, and with a median value of 1.0 (0.99, 1.0). In the
non-linearmodel HMA (n= 346), all passed the built-
in quality test. The difference in measured and esti-
mated FENO50 ranged from−5.0 to 5.0, with amedian
value of 0.3 (−0.6, 1.3) ppb.
NOparameters in the different age groups
There were statistically signiﬁcant differences in the
distribution of the NO parameters between the young,
middle and older age groups (table 2). FENO50 was
higher in the older age group compared to the young
age group (p < 0.001) and the middle age group
(p= 0.001), and FENO50 was higher in the middle age
group than the younger age group (p< 0.001). JawNO
was lower in the young age group compared to the
middle age (p < 0.001) as well as the older age group
(p< 0.001). CawNO was higher in the older age group
compared to the young age group (p< 0.001) and the
middle age group (p< 0.001), and CawNO was higher
in the middle age group than in the younger age group
(p < 0.001). DawNO was lower in the older age group
compared to the young age group (p= 0.023) and the
middle age group (p= 0.001). CANO was lower in the
middle age group compared to the young age group
(p= 0.001) and the older age group (p< 0.001).
NOparameters in the different age groups by gender
There was only a difference between genders in the
middle age group in FENO50 (p< 0.001), JawNO
(p< 0.001), CawNO (p< 0.001) and CANO
(p= 0.027) but not inDawNO (table 3).
Regression analyses
Relationships between age and the NO parameters
(JawNO, CANO, DawNO and CawNO), with univariate
regression lines and estimated 95% reference intervals,
are shown in ﬁgure 1. FENO50 is shown in the
supplementarymaterial, available online.
The multiple regression analyses, with the boot-
strap validation step, showed in the age groups above
20 years that age, height and gender interactions toge-
ther explained 6% of variation in FENO50, 4% in
JawNO, 16% in CawNO, 8% in DawNO and 12% in
CANO (table 4). Age was a signiﬁcant predictor in all
models (p < 0.001) except for JawNO (p = 0.18)
(table 4). The association was positive for FENO50 and
all NOparameters. Gender contributed as a signiﬁcant
main effect for CawNO and CANO only. Multiple lin-
ear regressionmodels poorly predicted the large varia-
tions in FENO50 andNOparameters.
In the age group<20 years there were only 83 sub-
jects and thereforemultiple regressionmodels were not
applied. Age correlated positively to FENO50 (r = 0.31,
p = 0.005) and to JawNO (r = 0.32, p = 0.003). There
were stronger correlations between height and FENO50
(r= 0.45, p< 0.001), and height and JawNO (r= 0.41,
p = 0.001), while no correlations were found between
height andCANO,CawNOandDawNO.
Table 1. Subject characteristics in the different age groups presented by gender.
Age group
<20 yrs 20–49 yrs 50 yrs
Gender Female Male Female Male Female Male
Subjects, n 41 42 82 113 42 113
Age, years 10 (9, 11) 10 (8, 12) 33 (26, 40) 39 (30, 44) 53 (52, 60) 56 (52, 65)
Height,m 1.39 (1.32, 1.47) 1.37 (1.31, 1.49) 1.68 (1.64, 1.71) 1.81 (1.75, 1.85) 1.67 (1.63, 1.69) 1.76 (1.72, 1.80)
Weight, kg 34 (30, 38) 32 (28, 39) 60 (55, 68) 80 (73, 87) 70 (61, 76) 79 (73, 88)
BMI, kg/m2 17 (16, 19) 17 (16, 19) 22 (20, 23) 25 (23, 26) 25 (23, 27) 26 (24, 28)
Data are given inmedian (25, 75 percentile).
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Discussion
In this study we have generated reference values for
NO parameters from an extended NO analysis of
healthy subjects. By pooling the healthy subjects’ data
from earlier published data the values of NO para-
meters for a large group of subjects can be presented.
We have found that age inﬂuences FENO and all the
NO parameters, while gender affects NO parameters
only in the middle age group. Multiple linear regres-
sion models poorly predicted the large variations in
FENO50 and NO parameters. In the See et al paper
(n= 13.275) about 10% of the variation in FENO was
explained by a variety of variables [35], and this is in
line with the current results (n= 433)where about 6%
of the variation in FENO50 was explained by age,
height, gender, NOmodel and study centre.
Lungdevelopment
In the <20 age group, FENO50 and the airway NO
parameters JawNO and CawNO were lower than in the
other age groups. This could possibly reﬂect an increas-
ing mucosal surface area with increasing height and
growing lung volumes. This was also present in the study
by Jacinto et al where the FENO50 increase breakpoint
appeared around 14 years in girls and 16 years in boys
[17]. This is in line with the growth of the body, and
more speciﬁcally the development of the bronchial tree.
Ageing
In the middle and older age groups pulmonary aging
seems to increase CANO. This possibly reﬂects
decreased diffusivity of gases in the distal portion of
the lung, as CANO is determined not only by factors
producing NO in the lung periphery but also by how
much alveolar NO can diffuse into the pulmonary
circulation where it is rapidly scavenged by haemoglo-
bin. In older age, the diffusing capacity declines in a
linear fashion with increasing age [21] and in elderly
healthy subjects there is a decrease in steady-state
transfer capacity for carbon monoxide (CO) [36] and
NO [37]. There is also an increase in residual volume
Table 2.Mean values and percentile distribution of FENO50 andNOparameters in the three age groups.
Percentile distribution
Age groups Mean p-value* 2.5 5 25 50 75 95 97.5
1FENO50, ppb
<20 yrs 10.8 <0.001 4.7 4.9 7.1 10.5 15.9 25.6 27.0
20–49 yrs 16.0 6.6 7.4 12.0 15.3 20.9 38.0 45.5
50 yrs 18.2 7.7 8.5 13.2 18.2 25.3 36.5 44.9
1JawNO, nl/s
<20 yrs 0.40 <0.001 0.08 0.10 0.26 0.38 0.66 1.36 1.60
20–49 yrs 0.76 0.31 0.34 0.53 0.70 1.08 2.01 2.51
50 yrs 0.81 0.27 0.31 0.52 0.83 1.23 2.00 2.23
1CawNO, ppb
<20 yrs 64 <0.001 19 21 34 58 123 208 439
20–49 yrs 105 30 35 65 105 160 309 441
50 yrs 155 40 51 89 150 267 491 535
1DawNO,ml/s
<20 yrs 7.5 0.002 0.9 1.3 4.8 8.7 13.1 25.6 26.9
20–49 yrs 7.8 1.3 2.5 5.3 8.3 12.7 19.1 21.6
50 yrs 5.7 1.0 1.2 3.5 6.2 10.3 17.1 20.8
CANO, ppb
<20 yrs 2.07 <0.001 0.11 0.61 1.52 2.05 2.73 3.59 3.88
20–49 yrs 1.72 0.21 0.29 1.13 1.61 2.23 3.66 3.93
50 yrs 2.2 0.33 0.51 1.48 2.25 2.85 3.77 3.88
1 Data with skewed distribution are given in geometrical mean, * Kruskal-Wallis test for difference in mean values between
age groups.
Table 3. FENO50 andNOparameters in the different age groups presented by gender.
Age group
<20 yrs 20–49 yrs 50 yrs
Gender Female Male Female Male Female Male
1FENO50, ppb 11 (8, 16) 10 (7, 15) 13 (10, 17) 18 (13, 23)
* 17 (12, 23) 19 (14, 26)
1JawNO, nL/s 0.43 (0.28, 0.66) 0.37 (0.23, 0.66) 0.63 (0.44, 0.83) 0.87 (0.60, 1.25)
* 0.75 (0.49, 1.14) 0.84 (0.54, 1.26)
1CawNO, ppb 76 (48, 130) 54 (30, 84) 77 (54, 115) 126 (77, 211)
* 121 (71, 173) 163 (100, 288)
1DawNO,ml/s 6.5 (4.0, 10.9) 8.7 (5.5, 17, 4) 8.8 (6.2, 12.8) 7.3 (4.8, 12.7) 7.1 (4.8, 11.4) 5.4 (3.2, 9.8)
CANO, ppb 2.12 (1.78, 2.39) 1.98 (1.25, 2.33) 1.99 (1.22, 2.39) 1.52 (1.07, 2.06)
* 2.44 (1.25, 2.92) 2.20 (1.45, 2.83)
Data are given inmedian (25,75 percentile). 1 Geometricalmean.Mann-WhitneyU-test for gender differences, * p< 0.05.
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Figure 1.Relationship between age and theNOparameters, airwayNOﬂux (JawNO), alveolarNO (CANO), airway diffusing capacity
(DawNO) and airwaywall content (CawNO), with univariate regression lines and estimated 95% reference intervals. Since children
differmarkedly from adults, in particular regarding the associations between height and age, the young age groupwas treated
separately.
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[38] reﬂecting obstruction of the distal part of the
airways that could possibly contribute to the increase
in CANO seen in this study. Thus, there is an
accumulation of NO from the alveolar region together
with the inhaled NO from the airways that increases
with age, and both can contribute to the increase of
CANO. However, the uptake of NO in pulmonary
capillaries is very high [39], and the increase in CANO
could also be due to other causes. One of these other
causes affecting CANO may be that clinically healthy
older subjects have an altered inﬂammatory cell proﬁle
and can actually have a low-grade inﬂammation in the
lower respiratory tract [40]. This could be due to the
macrophages becoming less efﬁcient in scavenging
invading microorganisms in older age groups [41, 42].
This could be an explanation for the increased exhaled
FENO50 and NO parameters, i.e. JawNO, CawNO and
CANO, in our older subjects.
In studies with older unhealthy patients, it is impor-
tant that the control subjects bematched to them by age
until there is enough data for this age group. Therefore,
the increased CANO that has been found in COPD
patients should be re-evaluated since they have been
compared in some studies to younger individuals
[10, 13]. However, in other studies, e.g. in cases of sys-
temic sclerosis or alveolitis, the CANO values are surely
increased since there were no age differences between
the patients and control subjects [12, 14, 43]. Matching
by gender should also be taken into account for themid-
dle age group, since CANO increases earlier in females.
This is possibly explained by a decrease in the capillary
blood volume of the lung [44] causing an impaired gas
exchange inwomen in themiddle age group.
DawNO decreased with increasing age. This is
interesting, as DawNO is the total diffusivity of NO
from bronchial mucosa to luminal air, and it can be
assumed to reﬂect both the total surface area available
for diffusion and also the physical properties of the
mucosa affecting the diffusivity of gases. As individuals
grow so do their bronchial trees, and one would
assume that DawNO increases with increasing height,
but we did not see this. Instead, we found that CawNO
increased and this explained the increase in JawNO and
FENO50 during the growth period. The decrease of
DawNO found in older age might reﬂect the physical
changes occurring in the bronchial mucosa of the
aging lung.
Gender
It was only in the middle age group where a gender
difference could be found in FENO50, JawNO, CawNO
andCANO. In the regressionmodel only the variations
inCawNOandCANOwere signiﬁcant for gender.
Olin et al found FENO50 to be higher in men than
in women around 50 years of age with 18 resp. 15 ppb
respectively, but when comparing FENO50 between
the sexes with similar heights and ages no difference
was found [16]. Jacinto et al have shown a gender dif-
ference in the same age group with men slightly above
15 ppb and women around 12 ppb [17]. The corresp-
onding values for FENO50 in the present study with the
young age group excluded are 16 ppb for men and
15 ppb for women, which are in line with the values
obtained by Olin et al using the same analysing
method, namely chemiluminescence.
A limitation in this study is that data were pooled,
which resulted inmoremen thanwomen, especially in
the old age group. In addition, the cross-sectional
design of the study is not optimal to assess the relation
between age and NO parameters. However, long
enough longitudinal studies would require decades of
follow-up. It would be interesting to put lung function
in relation to the NO parameters, but unfortunately
we did not have lung function data from all of the sub-
jects.We did check that there was no signiﬁcant differ-
ence in the mean FENO50 values between the different
centres, which suggests that the methodology was
similar enough to allow for the pooling of the data.
In conclusion, in this study we have generated
reference values for NO parameters from an extended
NO analysis of healthy subjects. This is important in
order to be able to use these parameters in clinical
practice. We found that pulmonary aging seems to
increase CANO, which is possibly a reﬂection of a
decreased diffusivity of gases in the gas exchange area.
The impaired immune defence system that occurs
with old age could also explain the increase in all NO
parameters except DawNO that was decreased in this
group. Further studies or additional pooling of data
are needed before we can provide even better age-rela-
ted reference values for the NO parameters and
Table 4.Regression coefﬁcents (B) and p-values of themultiple regressionmodels forNO-variables. The R2 is the unadjusted
coefﬁcient of determination of themodels and R2boot is the corresponding optimism-corrected R
2 values as estimated by
bootstrapping.
Intercept
Age Height Gender (male)
B B p-value B p-value B p-value R2 R2boot
FENO50 ppb 15.8 1.07 <0.001 1.04 0.29 1.12 0.13 0.08 0.06
JawNOnl/s 0.77 1.03 0.18 1.05 0.33 1.10 0.26 0.07 0.04
CawNOppb 86.6 1.16 <0.001 0.87 0.04 1.70 <0.001 0.19 0.16
DawNOml/s 8.6 0.88 <0.001 1.21 0.01 0.69 0.01 0.11 0.08
CANOppb 1.95 0.2 <0.001 −0.03 0.68 −0.24 0.09 0.15 0.12
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possibly create reliable reference equations. However,
this is currently the largest dataset for NO parameters
that can be used as a basis for comparisons in future
studies regarding health and disease.
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